ClinicalTrials.gg
RecruitingNCT06174987Updated Oct 26, 2026

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

A Phase 3 interventional study of T-DXd in Advanced Cancer and Metastatic Cancer, sponsored by Daiichi Sankyo. Recruiting at 34 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 26, 2026First sites in China, Hong Kong and Turkey (Türkiye)No longer in Belgium and United Kingdom+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis — 10 open to participants now, 13 under way, 2 of them phase 3. trastuzumab deruxtecan · Neoplasm Metastasis.

Planned enrollment
10th of 20
75 · median 69
Started
2024
the only one that year
Phase 3
3 of 20
1 open now
Primary completion
2028-02
later than 6 of 12 live
Registered
14th of 20
by date
Lead sponsor
6 of 20
Daiichi Sankyo

Among the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, this one is the 10th largest by planned enrollment, is the only one that started in 2024, is one of 3 in phase 3, reaches primary completion later than 6 of the 12 other live ones, and was the 14th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

10 of the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study.

Read the detailed description

This Master Rollover Study includes sub-protocols with different study drugs. This Master Rollover Protocol describes core study elements that are applicable to all study drugs that will be provided under the Rollover Study.

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer

Browse trials for

Keywords

  • Advanced cancer
  • Metastatic cancer
  • T-DXd
  • DS8201a
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  1. Currently enrolled in a DS or DS/AZ-sponsored parent study that has met EOS definition.
  2. No evidence of progressive disease at screening and determined to have investigator-assessed clinical benefit from continued treatment with a DS or DS/AZ alliance study drug(s).
  3. Male and female subjects of reproductive/ must agree to use a highly effective form of or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug.

    a. If the participant is a female of childbearing potential, she must have a negative urine pregnancy test at Screening, during the Treatment Period, and for 7 months, following the last dose of study drug.

  4. Male subjects must not freeze or donate sperm starting at Screening, throughout the study period, and at least 4 months after the final study drug administration.
  5. Female subjects must not donate, or retrieve for their own use, ova from the time of Screening, and throughout the Treatment Period in the compound-specific sub-protocol and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Participants who permanently discontinued from the study drug in the parent study.
  2. Any AE, laboratory abnormality, or intercurrent illness that, in the opinion of the investigator, indicates study participation is not in the best interest of the subject.
  3. Local access to commercially available drug at no cost to the subject as permitted by local/country regulation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    T-DXd

    Participants who choose to continue treatment with T-DXd may be enrolled. Participants who were on the comparator arm in the parent study will be provided the option to access the drug through standard of care (SoC) or other available options. Participants will remain on their current dosage regimen of T-DXd as the last dose administered in the parent study, unless they experience an AE that requires dose reduction at the EOT of the parent study, in which case the starting dose in this study will be the next lower dose-level.

    Drug: T-DXd

Interventions

  • DrugT-DXd

    T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens

    Also known as: DS8201a

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-emergent Adverse Events Leading to Study Drug discontinuation and/or Dose Reduction, Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (AESIs)

    Time frame: Baseline until disease progression, loss of clinical benefit, death, adverse event, pregnancy, withdrawal of consent, access to commercial supply, physician decision, or study closure, whichever occurs first, up to approximately 2 years 9 months

07

Study locations

1 of 34 sites recruiting
  • Research Facility
    Miami, Florida 33176, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Durham, North Carolina 27710, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Bedford Park, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Itajaí, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Rio de Janeiro, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    São Paulo, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Changchun, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Harbin, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Hefei, China
    Recruiting
  • Research Facility
    Lille, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Marseille, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Toulouse, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Villejuif, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Hong Kong, Hong Kong
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Petah Tikva, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Aviano, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Milan, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Rozzano, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Chūōku, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Kashiwa-shi, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Daegu, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Goyang-si, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Seoul, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    A Coruña, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Barcelona, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Madrid, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Tainan, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Taipei, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Adana, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Ankara, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Antalya, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Diyarbakır, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Istanbul, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Facility
    Tekirdağ, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Feb 2028, 49 months after the start.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's planned 49 months is above that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Aug 2026 → Feb 2028 and completion Jan 2028 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Dec 18, 2023
StartActual
Jan 5, 2024
Primary completionEst.
Feb 17, 2028was Aug 2026
CompletionEst.
Feb 17, 2028was Jan 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
34 sites added, 28 sites removed — first sites in China, Hong Kong and Turkey (Türkiye); no longer in Belgium and United Kingdom
Show 34 added (6 Turkey (Türkiye), 4 France, 3 Brazil, 3 China, 3 Italy, 3 South Korea, 3 Spain, 2 United States, 2 Japan, 2 Taiwan, 1 Australia, 1 Hong Kong, 1 Israel)
  • Research Facility · Miami, United States
  • Research Facility · Durham, United States
  • Research Facility · Bedford Park, Australia
  • Research Facility · Itajaí, Brazil
  • Research Facility · Rio de Janeiro, Brazil
  • Research Facility · São Paulo, Brazil
  • Research Facility · Changchun, China
  • Research Facility · Harbin, China
  • Research Facility · Hefei, China
  • Research Facility · Lille, France
  • Research Facility · Marseille, France
  • Research Facility · Toulouse, France
  • Research Facility · Villejuif, France
  • Research Facility · Hong Kong, Hong Kong
  • Research Facility · Petah Tikva, Israel
  • Research Facility · Aviano, Italy
  • Research Facility · Milan, Italy
  • Research Facility · Rozzano, Italy
  • Research Facility · Chūōku, Japan
  • Research Facility · Kashiwa-shi, Japan
  • Research Facility · Daegu, South Korea
  • Research Facility · Goyang-si, South Korea
  • Research Facility · Seoul, South Korea
  • Research Facility · A Coruña, Spain
  • Research Facility · Barcelona, Spain
  • Research Facility · Madrid, Spain
  • Research Facility · Tainan, Taiwan
  • Research Facility · Taipei, Taiwan
  • Research Facility · Adana, Turkey (Türkiye)
  • Research Facility · Ankara, Turkey (Türkiye)
  • …and 4 more on the registry record
Show 28 removed
  • Miami Cancer Institute · Miami, United States
  • Duke University - Trent Center · Durham, United States
  • Flinders Medical Center · Bedford Park, Australia
  • Monash Medical Center · Melbourne, Australia
  • Grand Hôpital de Charleroi · Charleroi, Belgium
  • Instituto Aericas · Rio de Janeiro, Brazil
  • A.C. Camargo Cancer Center · São Paulo, Brazil
  • IBCC Nucleo de Pequisa e Ensino · São Paulo, Brazil
  • Institut Gustave Roussy · Villejuif, France
  • Rabin Medical Center · Petah Tikva, Israel
  • Ospedale San Raffaele · Milan, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale · Naples, Italy
  • National Cancer Center Hospital · Chūō, Japan
  • Kyungpook National University Chilgok Hospital · Daegu, South Korea
  • National Cancer Center · Gyeonggi-do, South Korea
  • Seoul National University Bundang Hospital · Gyeonggi-do, South Korea
  • Seoul National University Hospital · Jongno-gu, South Korea
  • Severance Hospital, Yonsei University · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Complejo Hospitalario Universitario A Coruña · A Coruña, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Universitari Dexeus · Distrito de Les Corts, Spain
  • ICO l'Hospitalet - Hospital Duran i Reynals · L'Hospitalet de Llobregat, Spain
  • Hospital Ruber Internacional · Madrid, Spain
  • National Cheng Kung University Hospital · Tainan, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
  • Royal Surrey County Hospital · Guildford, United Kingdom
Oct 26, 2026
Primary completion
Aug 3, 2026→Feb 17, 2028
Oct 26, 2026
Study completion
Jan 17, 2028→Feb 17, 2028
Oct 26, 2026
Enrollment
50→75
Oct 26, 2026
Eligibility
1 inclusion criterion edited, 5 added, 1 removed; 4 exclusion criteria added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedSigned informed consent form, prior to the start of any study-specific qualification procedures and willing to comply with all study requirements.
  • AddedParticipants must meet all of the following criteria to be eligible for enrollment into the study:
  • EditedNo evidence of progressive disease at screening and determined to have investigator-assessed clinical benefit from continued treatment with a DS or DS/AZ alliance study drug(s).
  • AddedMale and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug.
  • AddedIf the participant is a female of childbearing potential, she must have a negative urine pregnancy test at Screening, during the Treatment Period, and for 7 months, following the last dose of study drug.
  • AddedMale subjects must not freeze or donate sperm starting at Screening, throughout the study period, and at least 4 months after the final study drug administration.
  • AddedFemale subjects must not donate, or retrieve for their own use, ova from the time of Screening, and throughout the Treatment Period in the compound-specific sub-protocol and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time.
Exclusion criteria
  • RemovedParticipants with any unresolved/ongoing AE(s) that meets the study drug discontinuation criteria
  • RemovedParticipant who has been off T-DXd therapy for >18 weeks (126 days) between the last dose from the parent study and the initiation of study drug administration on this study
  • AddedParticipants who meet any of the following criteria will be disqualified from entering the study:
  • AddedParticipants who permanently discontinued from the study drug in the parent study.
  • AddedAny AE, laboratory abnormality, or intercurrent illness that, in the opinion of the investigator, indicates study participation is not in the best interest of the subject.
  • AddedLocal access to commercially available drug at no cost to the subject as permitted by local/country regulation.
Oct 26, 2026
Contact
Study contact's phone or email changed: C•••@dsi.com→C•••@daiichisankyo.com. See the current contact
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    34 sites added, 28 sites removed — first sites in China, Hong Kong and Turkey (Türkiye); no longer in Belgium and United Kingdom
    Show 34 added (6 Turkey (Türkiye), 4 France, 3 Brazil, 3 China, 3 Italy, 3 South Korea, 3 Spain, 2 United States, 2 Japan, 2 Taiwan, 1 Australia, 1 Hong Kong, 1 Israel)
    • Research Facility · Miami, United States
    • Research Facility · Durham, United States
    • Research Facility · Bedford Park, Australia
    • Research Facility · Itajaí, Brazil
    • Research Facility · Rio de Janeiro, Brazil
    • Research Facility · São Paulo, Brazil
    • Research Facility · Changchun, China
    • Research Facility · Harbin, China
    • Research Facility · Hefei, China
    • Research Facility · Lille, France
    • Research Facility · Marseille, France
    • Research Facility · Toulouse, France
    • Research Facility · Villejuif, France
    • Research Facility · Hong Kong, Hong Kong
    • Research Facility · Petah Tikva, Israel
    • Research Facility · Aviano, Italy
    • Research Facility · Milan, Italy
    • Research Facility · Rozzano, Italy
    • Research Facility · Chūōku, Japan
    • Research Facility · Kashiwa-shi, Japan
    • Research Facility · Daegu, South Korea
    • Research Facility · Goyang-si, South Korea
    • Research Facility · Seoul, South Korea
    • Research Facility · A Coruña, Spain
    • Research Facility · Barcelona, Spain
    • Research Facility · Madrid, Spain
    • Research Facility · Tainan, Taiwan
    • Research Facility · Taipei, Taiwan
    • Research Facility · Adana, Turkey (Türkiye)
    • Research Facility · Ankara, Turkey (Türkiye)
    • …and 4 more on the registry record
    Show 28 removed
    • Miami Cancer Institute · Miami, United States
    • Duke University - Trent Center · Durham, United States
    • Flinders Medical Center · Bedford Park, Australia
    • Monash Medical Center · Melbourne, Australia
    • Grand Hôpital de Charleroi · Charleroi, Belgium
    • Instituto Aericas · Rio de Janeiro, Brazil
    • A.C. Camargo Cancer Center · São Paulo, Brazil
    • IBCC Nucleo de Pequisa e Ensino · São Paulo, Brazil
    • Institut Gustave Roussy · Villejuif, France
    • Rabin Medical Center · Petah Tikva, Israel
    • Ospedale San Raffaele · Milan, Italy
    • Istituto Nazionale Tumori Fondazione G. Pascale · Naples, Italy
    • National Cancer Center Hospital · Chūō, Japan
    • Kyungpook National University Chilgok Hospital · Daegu, South Korea
    • National Cancer Center · Gyeonggi-do, South Korea
    • Seoul National University Bundang Hospital · Gyeonggi-do, South Korea
    • Seoul National University Hospital · Jongno-gu, South Korea
    • Severance Hospital, Yonsei University · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Complejo Hospitalario Universitario A Coruña · A Coruña, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Universitari Dexeus · Distrito de Les Corts, Spain
    • ICO l'Hospitalet - Hospital Duran i Reynals · L'Hospitalet de Llobregat, Spain
    • Hospital Ruber Internacional · Madrid, Spain
    • National Cheng Kung University Hospital · Tainan, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    • Royal Surrey County Hospital · Guildford, United Kingdom
    Primary completion Aug 3, 2026→Feb 17, 2028
    Study completion Jan 17, 2028→Feb 17, 2028
    Enrollment 50→75
    Eligibility 1 inclusion criterion edited, 5 added, 1 removed; 4 exclusion criteria added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedSigned informed consent form, prior to the start of any study-specific qualification procedures and willing to comply with all study requirements.
    • AddedParticipants must meet all of the following criteria to be eligible for enrollment into the study:
    • EditedNo evidence of progressive disease at screening and determined to have investigator-assessed clinical benefit from continued treatment with a DS or DS/AZ alliance study drug(s).
    • AddedMale and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug.
    • AddedIf the participant is a female of childbearing potential, she must have a negative urine pregnancy test at Screening, during the Treatment Period, and for 7 months, following the last dose of study drug.
    • AddedMale subjects must not freeze or donate sperm starting at Screening, throughout the study period, and at least 4 months after the final study drug administration.
    • AddedFemale subjects must not donate, or retrieve for their own use, ova from the time of Screening, and throughout the Treatment Period in the compound-specific sub-protocol and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time.
    Exclusion criteria
    • RemovedParticipants with any unresolved/ongoing AE(s) that meets the study drug discontinuation criteria
    • RemovedParticipant who has been off T-DXd therapy for >18 weeks (126 days) between the last dose from the parent study and the initiation of study drug administration on this study
    • AddedParticipants who meet any of the following criteria will be disqualified from entering the study:
    • AddedParticipants who permanently discontinued from the study drug in the parent study.
    • AddedAny AE, laboratory abnormality, or intercurrent illness that, in the opinion of the investigator, indicates study participation is not in the best interest of the subject.
    • AddedLocal access to commercially available drug at no cost to the subject as permitted by local/country regulation.
    Contact Study contact's phone or email changed: C•••@dsi.com→C•••@daiichisankyo.com. See the current contact
    + 4 other changes: identifiers, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06174987
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Jan 5, 2024
Primary completion
Feb 17, 2028 (estimated)
Completion
Feb 17, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400
Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion